More pediatric patients free of new or newly enlarging T2 lesions at week 96 with dimethyl fumarate versus interferon beta-1a<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Oct. 6, 2022 (HealthDay News) — More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon \u00ce\u00b2-1a (IFN\u00ce\u00b2-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open<\/em>.<\/p>\n Patrick Vermersch, M.D., Ph.D., from the Centre Hospitalier Universitaire de Lille in France, and colleagues conducted an active-controlled, open-label randomized clinical trial involving patients with POMS aged 10 to <18 years. A total of 150 patients with POMS were randomly assigned to DMF or IFN\u00ce\u00b2-1a (78 and 72 individuals, respectively).<\/p>\n The researchers found that among the 103 trial completers, the proportion of patients with no N or NE T2 hyperintense lesions at week 96 was 16.1 and 4.9 percent for DMF and IFN\u00ce\u00b2-1a, respectively; in a sensitivity analysis among the intention-to-treat population, the proportions were 12.8 and 2.8 percent, respectively. The estimated proportion of patients who remained relapse-free was 66.2 and 52.3 percent for DMF and IFN\u00ce\u00b2-1a, respectively, at week 96. The adjusted annualized relapse rate was 0.24 and 0.53 for DMF and IFN\u00ce\u00b2-1a, respectively, at week 96; the rate ratio was 0.46 for DMF versus IFN\u00ce\u00b2-1a.<\/p>\n “The CONNECT randomized clinical trial found that DMF led to meaningful improvements in radiological and clinical outcomes in patients with POMS, with a positive benefit-risk balance,” the authors write.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Biogen, which manufactures dimethyl fumarate and funded the trial.<\/p>\n Abstract\/Full Text<\/a><\/p>\n